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Society of Clinical Oncology 2014 in Chicago – Expert 
Opinions Revisited
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Question 1: What Was Your Personal Highlight of 
the ASCO 2014 in Chicago?
Liedtke: If you had asked me before this year’s ASCO 
meeting had started, I probably would have mentioned the re-
sults of the ALTTO trial. However, since this study has to be 
called ‘negative’, I am afraid that regarding breast cancer 
treatment I did not see one single highlight but rather once 
again many small pieces of the final puzzle. These pieces, 
however, are almost as important as the results of large rand-
omized trials since they may provide us with novel insights 
into the biology of breast carcinoma and thereby may provide 
the basis for novel therapeutic concepts.
Thill: In my opinion, it is not possible to define a single 
highlight and the so-called highlights presented were negative 
(ALTTO trial) or not really mature results (SOFT/TEXT tri-
als). Data that I would highlight have been collected in pre-
menopausal patients. The first trial was the pooled analysis of 
the SOFT and TEXT trials with an improvement in disease-
free survival (DFS) of premenopausal patients who were 
treated with exemestane and triptorelin compared to the com-
bination with tamoxifen. These are surprising results as we 
already learned from the ABCSG-12 study that the combina-
tion of an aromatase inhibitor and a GnRH analogue has no 
benefit in premenopausal patients. However, a lot of data 
from the SOFT trial are lacking and the time of accrual was 
very long. Therefore, these are currently no practice changing 
data in my opinion. The second highlight was the POEMS 
The Annual Meeting of the American Society of Clinical 
Oncology (ASCO) 2014 May 30 to June 3 at McCormick Place 
in Chicago, Illinois, was again both the largest meeting in on-
cology, and also overwhelming in the variety of scientific pres-
entations as well as of educational and other sources of infor-
mation. Moreover, it was a special meeting – ASCO celebrates 
50 years of advancing progress against cancer. The meeting was 
founded at a small lunch meeting on April 9, 1964. At the time 
of the first meeting, the landscape of cancer was ominous: can-
cer was widely regarded as a monolithic, largely untreatable 
disease. Much has changed since 1964. Today cancer is treated 
interdisciplinarily with modern therapeutic concepts. Efficacy 
is increasing and side effects become less and manageable. 
Especially gynecological cancers and breast cancer are in the 
focus of research and clinical trials. In Germany, these cancers 
affect 97,480 women every year, 43% of all cancer cases in 
women. Thus, gynecology has a special value in oncological 
care. Gynecological oncology and mastology have evolved 
dramatically in several directions corresponding to their im-
portance in oncological care. This concerns modern diagnos-
tics on which individual treatment plans are based (e.g. genetic 
subtypes in breast cancer), as well as the current multimodal 
and interdisciplinary treatment concepts. These aspects are 
also important for the ASCO – numerous results from clinical 
trials and further scientific data have been presented at this 
year’s meeting. 
We asked 5 German experts about their bottom line of the 
ASCO 2014 meeting on 5 main questions concerning breast 
cancer.
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study which has compared a cyclophosphamide containing 
chemotherapy with and without goserelin to prevent prema-
ture ovarian failure. The results presented by Halle Moore 
show, besides a surprisingly high pregnancy rate for the goser-
elin arm, an improved DFS and overall survival (OS) with 
goserelin. Due to these results, I think, it is an option to offer 
ovarian function suppression (OFS) for hormone-receptor 
negative patients who desire future fertility.
Müller: The oral presentation of the first results of BRCA 
mutation analysis from the triple negative (TNBC) cohort of 
the GeparSixto neoadjuvant trial is my personal highlight of 
the meeting. The presented analysis examined the correlation 
of germline BRCA alterations and family history for breast 
and ovarian cancer with the pathological complete response 
(pCR) rate in patients with TNBC. This question is of clinical 
relevance since there is a need for improvement of treatment 
outcome especially in TNBC but a lack of predictive factors 
for an increased benefit from carboplatin containing thera-
pies. Alterations of BRCA or RAD50/51 were detected in at 
least 15% of the participants with TNBC in the GeparSixto 
trial. Patients with no further risk factors achieved a pCR rate 
of 40%. The pCR rate tended to be higher in patients with 
family history of breast and ovarian cancer (49%, p = 0.21) or 
germline BRCA/RAD alterations (55%, p = 0.11). The high-
est pCR rate was observed in patients with both (64%). This 
indicates a special biology of the tumor of these patients and 
might help to optimize future treatment.
Siebert: One personal highlight of the ASCO 2014 in 
Chicago was the reflection on global oncological questions by 
the charismatic Nobel prize and this year’s ASCO award win-
ner Harald zur Hausen simply using bibliographical refer-
ences such as ‘Wikipedia’. Medicine does not necessarily in-
volve complex cellular processes, but can sometimes be basic 
and simple. One main statement was that the consumption of 
red meat seems to be linked with colorectal cancer and other 
tumor entities due to virus interactions with carcinogens 
formed during cooking.
Kern: The Science of Oncology Award of the ASCO 
Annual Meeting 2014 granted to Harald zur Hausen for his 
lifetime achievements and outstanding lecture ‘Do some 
Human Cancers Originate from Infections Transmitted from 
Domestic Animals?’ was my personal highlight of this ASCO 
Annual Meeting. I had the opportunity to encounter his re-
search activities on this field at ESGO in Belgrade in the year 
2009, when he already suggested an association of gastric, 
pancreatic, colon, breast, and lung cancer citing numerous co-
hort and case control studies. Regarding premenopausal 
women with breast cancer, he presented 14 consistently posi-
tive studies – 4 cohort trials and more than 7 case cohort trials 
– which showed an odds ratio for risk by consumption of red 
meat of 1.11 (case cohort) to 1.57 (case control). In his presen-
tation he demonstrated own hypotheses by exploring the inci-
dence and prevalence of cancer subtypes in various countries 
and their respective habits of eating red meat, followed by vi-
rological analyses and the identification of polyoma viruses 
associated with the carcinogenesis of the tumors mentioned 
above. Similarly, like the discovery of the association of the 
HPV high-risk infections and the carcinogenesis of cervical 
cancer was initially rejected by the scientific community, how-
ever later awarded with the Nobel prize, zur Hausen plans to 
work on a vaccination for meat cattle. Until a special vaccina-
tion is available, considerations have to be made how to deal 
with zur Hausen’s findings of red meat consumption with re-
gard to daily dietary recommendations.
Question 2: Which Changes Do You See for the 
Neoadjuvant and Adjuvant Treatment of Breast 
Cancer Patients in the Coming Year That Are 
Triggered by the ASCO Meeting? 
Liedtke: Pagani and colleagues presented the results of the 
TEXT/SOFT joint analysis which demonstrated that preme-
nopausal patients with breast cancer treated with aromatase 
inhibitors and OFS had a superior outcome (regarding dis-
ease-free, distant disease-free and breast cancer-free survival) 
compared to patients treated with tamoxifen and OFS. At 
first glance, these results appear practice changing. However, 
one has to acknowledge that there is a lack of comparisons 
with today’s standard therapy, i.e. tamoxifen alone against 
these 2 OFS based combinations, before we can make a judg-
ment regarding a potential novel standard therapeutic ap-
proach. However, in patients with contraindications against 
tamoxifen, TEXT/SOFT represent an additional piece of data 
that OFS in combination with an aromatase inhibitor may be 
a safe alternative for premenopausal breast cancer patients.
Müller: One surprising result was the presentation by 
Pagani et al. about the first results of the TEXT and SOFT tri-
als. With this joint analysis of 4,690 premenopausal patients, 
the comparison of tamoxifen versus exemestane, each given in 
combination with OFS for 5 years was also published in the 
New England Journal of Medicine on the same day. With a 
median follow up of 5.7 years, a significant increase of the re-
currence-free interval was observed with a hazard ratio of 
0.66 and an absolute benefit of 4%. Also surprisingly for me, 
the quality of life was similar in both treatment arms. My feel-
ing is that patients experience more side effects with aro-
matase inhibitors and OFS compared to tamoxifen and OFS. 
Regarding the follow up, no difference in overall survival was 
observed. In my opinion, the combination of exemestane and 
OFS is not the new standard due to the lack of survival advan-
tage and possible relevant side effects. The role of OFS in ad-
dition to tamoxifen compared to tamoxifen alone still remains 
unclear since this treatment arm was not presented. However, 
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In the adjuvant setting, I consider the data of Chiara 
O’Sullivan as confirmation not to withhold trastuzumab from 
patients with Her2/neu-positive breast cancers smaller than 2 
cm, since a benefit is conveyed in the hormone receptor-posi-
tive and -negative setting. She compared the trastuzumab con-
taining arms with no trastuzumab in patients with tumors ≤ 2 
cm from 5 randomized trials (HERA, NCCTG N9831, 
NSABP B31, PACS 04, and FinHER). Patients with smaller 
tumors benefited substantially – both in terms of DFS and OS 
– from trastuzumab therapy. However, the authors indicated 
that almost all patients in these trials had T1c disease and pos-
itive lymph nodes, which represents a selected group of 
patients.
Eric P. Winer discussed his thoughts on Her2/neu-positive 
breast cancers < 1 cm and presented his ‘Eric’s Equation’. He 
suggests that pT1a tumors – if hormone receptor-positive – 
should to be treated without trastuzumab and chemotherapy. 
I asked him whether he would also leave these tumors un-
treated in case of disseminated Her2/neu-positive tumor cells 
(DTC) of the bone marrow. He replied that he did not per-
form a bone marrow aspiration for DTC detection so far, but 
agreed that also the data from the German SUCCESS trial 
have demonstrated the negative prognostic value of positive 
DTCs which could contribute to a worse prognosis even in 
these smaller tumors.
Question 3: In which Way Can the ASCO Meeting 
Influence the Future Treatment of Metastatic Breast 
Cancer?
Müller: I did not realize practice changing results for the 
therapy of patients with metastatic breast cancer.
Liedtke: I have a feeling that every breast cancer meeting 
introduces one novel agent to the broader audience. This 
year’s new drug was trebananib, an anti-angiogenic small mol-
ecule which has been analyzed in combination with trastu-
zumab and paclitaxel in the treatment in Her2/neu-positive 
metastatic breast cancer patients as part of a phase Ib clinical 
trial. This agent demonstrates promising response rates.
Thill: Many new compounds were presented, partially with 
promising but also with negative results. Combination thera-
pies to overcome endocrine resistance will be very valuable in 
future. Promising approaches are the inhibition of CDK 4/6, 
FGFR or PI3K. No data were presented to change our cur-
rent treatment of the triple negative subtype. However, the 
use of homologues recombinant deficiency (HRD) assays 
help to identify sporadic triple negative tumors which are sim-
ilar to BRCA1/2 mutation associated cancer and react to plat-
inum salts. Moreover, it is crucial to identify further biomark-
ers and driver mutations in the future. However, the SAFIR 
01 trial presented current difficulties. 
it is reassuring to know we can offer this treatment to patients 
that have a contraindication against tamoxifen.
Thill: This year’s ASCO confirmed that bevacizumab does 
not achieve any survival benefit in the adjuvant setting. Kathy 
Miller presented the data of the E5103 trial. Neither DFS nor 
OS was improved by the addition of bevacizumab to an an-
thracycline/taxane containing regimen. Similar results have 
been presented by the BETH and BEATRICE trials. 
However, it is one of my standard compounds in the treatment 
of metastatic breast cancer (mBC). Regarding the neoadjuvant 
setting, Gunter von Minckwitz showed that the highest pCR 
rate amongst the triple negative group of the GeparSixto trial 
could be achieved in patients with both a family history of 
breast and ovarian cancer and alterations in BRCA/RAD. 
These data were confirmed by Paluch-Shimon and colleagues 
who described the highest pCR rate in BRCA1/2 patients, but 
no prediction of the relapse-free survival by pCR. 
It is getting more and more important to test TNBC pa-
tients for BRCA mutations. However, we also have to con-
sider the currently known Lehmann subtypes of TNBC which 
predict the response to neoadjuvant chemotherapy. Certainly, 
the differentiation in Lehmann subtypes has to be done by 
our pathologists in the future.
Siebert: The addition of carboplatin to the cytostatic ther-
apy in TNBC – especially in patients with BRCA-mutated or 
hereditary disease – as shown by Gunter von Minckwitz with 
the results of the GeparSixto trial – demonstrated an increase 
of more than 20% in pCR. In future, the 2014 ASCO Meeting 
will surely trigger this change in neoadjuvant (and maybe ad-
juvant) treatment of this group of breast cancer patients.
Kern: Regarding the neoadjuvant setting, I see changes in 
the treatment of TNBC patients with familial history of breast 
and/or ovarian cancer with and without germline mutations of 
BRCA/RAD towards the inclusion of carboplatin to an an-
thracycline and taxane containing regimen. A pCR rate of 
66.7% is achieved even with a strict definition of pCR (yp-
T0ypN0) and with regard to both conditions. Carboplatin 
achieves an increase of 23.2% of the pCR rate, and in case of 
a familial history without mutation an increase of 26.7% with 
a pCR rate of 57.5%. Even without any of these conditions an 
increase of pCR rate of 11.5% (from 34.5 to 46.0%) was de-
tected; but without statistical significance, maybe due to the 
lower caseload. These findings correspond well with the over-
view of international data from the lecture of Melinda Telli 
(Stanford University), as well as with our own data which we 
presented at ASCO 2010 and published recently. Gunter von 
Minckwitz has proposed an effective carboplatin containing 
regimen with the GeparSixto trial, likewise William Sikov 
with the CALBG study 40603 at San Antonio Breast Cancer 
Symposium 2013, which may be chosen with regard to the re-
spective tolerability of the patient.
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Thill: In my opinion, the most disappointing results were 
the long awaited results of the ALTTO trial. We already have 
excellent results for a dual Her2/neu blockade in the meta-
static (CLEOPATRA) and in the neoadjuvant setting 
(NEOSPHERE). But, unfortunately, these excellent results 
could not be confirmed by the ALTTO study which has evalu-
ated the use of trastuzumab and lapatinib. More than 8,000 
patients were recruited. Both – trastuzumab in combination 
with lapatinib and trastuzumab followed by lapatinib – pre-
sented no significant difference in DFS. Besides the low-risk 
patient population, it was impressive to see an OS of 94–95% 
after 4.5 years due to the use of trastuzumab. However, the 
ALTTO results have to make us contemplative why results 
from the metastatic and the neoadjuvant setting are not re-
producible in in the adjuvant situation.
Siebert: ‘Disappointing’ is a quite severe term in my opin-
ion: The ‘off’ for the combined targeted therapy with trastu-
zumab and lapatinib analyzed by the ALTTO trial was not 
this unexpected since own experiences showed a high rate of 
toxicity at a questionable (now an objectively unproven) ben-
efit. My personal surprise is that we now discuss a shorter and 
more expensive alternative endocrine therapy with even 
higher side effects in premenopausal patients with a hormone 
sensitive breast cancer as a result of the TEXT trial. These 
results are in contrast to our new guideline which recom-
mends an extended therapy up to 10 years. 
Kern: The ALTTO trial was most disappointing, as it dem-
onstrated no role for double targeting with the addition of la-
patinib to trastuzumab in the adjuvant setting. This also cor-
responds with the role of lapatinib in the Neo-ALTTO trial.
Question 5: What Was the Most Important 
Contribution on Prognostic or Predictive Factors in 
Your Opinion?
Liedtke: I was excited to see the analysis of the GeparSixto 
trial presented by Gunter von Minckwitz and colleagues re-
garding the association between the BRCA mutation status 
and the response to neoadjuvant platinum containing chemo-
therapy in patients with TNBC. Although the majority of at-
tendants – including me – had a feeling that the benefit of 
platinum was confined to patients with hereditary carcinoma, 
we were surprised by the results demonstrating that BRCA/
RAD mutations alone did not predict a significantly better 
response to platinum-containing chemotherapy (pCR 43.5% 
vs. 66.7%, p = 0.13). Interestingly, the authors observed an 
increased pCR rate by carboplatin among patients without 
mutation but positive family history (pCR 30.8% vs. 57.5%, p 
= 0.02). These results, however, remain to be reproduced 
and, most of all, explained biologically. The AGO recom-
mends using platinum containing chemotherapy among pa-
Siebert: Recently we observed rapid progress especially in 
the management of advanced Her2/neu-positive breast can-
cer. Results from the ongoing MARIANNE trial suggest that 
trastuzumab emtasine (or ‘T-DM1’) has so far the potential to 
change the first-line therapy standard for Her2/neu-positive 
metastatic breast cancer patients due to supposed equivalent 
effectiveness combined with minimal toxicity.
Kern: In the Her2/neu-negative, hormone sensitive, meta-
static setting, there is an evolving role of CDK 4/6 inhibition 
(palbociclib) which resulted in a 4 times prolonged progres-
sion-free survival in studies so far. In the Her2/neu-positive, 
metastatic setting, double targeting has also markedly pro-
longed progression free survival, and – by the optimal se-
quence of Her2/neu directed therapies – rendered breast can-
cer a chronic disease which is controllable often almost over a 
decade. As Shanu Modi from the Memorial Sloan Kettering 
Cancer Center has pointed out, multiple Her2/neu directed 
therapies are in development (neratinib, afatinib, HSP90 in-
hibitors, PI3K inhibitors, such as BKM 120 and BEZ235), 
which can potentially add further years to the survival of pa-
tients in the metastatic setting.
Question 4: Which Results of Clinical Trials 
Presented at the ASCO Meeting Were Most 
Disappointing for You?
Liedtke: I guess that most of the audience would agree that 
the presentation of the results of the ALTTO trial were the 
most disappointing result of this year’s ASCO. Although the 
combination of lapatinib and trastuzumab has been shown to 
be more effective than either substance alone in the majority 
of studies in the metastatic and neoadjuvant setting, ALTTO 
demonstrated that the addition of lapatinib to trastuzumab 
did not enhance DFS in patients with Her2/neu-positive 
breast cancer in the adjuvant setting. Although there are sev-
eral explanations for these results, such as dose reductions of 
lapatinib due to toxicity, trastuzumab in combination with 
chemotherapy remains standard of care unless the results of 
ongoing trials such as APHINITY using pertuzumab will be 
presented.
Müller: The results of the adjuvant ALTTO trial were dis-
appointing in some ways. The addition of lapatinib to trastu-
zumab in the adjuvant treatment of Her2/neu-positive patients 
did not improve outcome. Importantly, the entire patient co-
hort had an excellent outcome with a 4-year DFS rate between 
86 and 88%. I think that the study does not allow the conclu-
sion that the concept of dual Her2/neu blockade is not more 
effective than trastuzumab treatment alone. The combination 
of other Her2/neu targeting drugs and/or a better selection of 
high-risk patients could provide an improvement in outcome. 
This is currently addressed by several ongoing trials.
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Kern: Harold Burstein presented the terminus of ‘Precision 
Medicine’ as ‘the use of genomic, epigenomic, exposure and 
other data to define individual patterns of disease, potentially 
leading to better individual treatment’ in the opening session 
of the ASCO Meeting 2014. The integration of genomic profil-
ing to treatment decisions by first generation gene arrays, e.g. 
Oncotype DX, and genetic changes identified by next genera-
tion sequencing will overturn our so far existing treatment al-
gorithms. Burstein showed that distinct subtypes of breast can-
cer have different repertoires of mutations, but there is no sub-
type specific highly mutated gene. So, parallel sequencing 
analyses of breast cancer tumors will be necessary to enable an 
individual portrait of each tumor before treatment.
Participants
Dr. Peter Kern
Universitätsklinikum Essen und 
Brustzentrum Düsseldorf im Luisenkrankenhaus
Hufelandstraße 55
45147 Essen, Germany 
Peter.Kern@uk-essen.de
PD Dr. med. Cornelia Liedtke
Klinik für Frauenheilkunde und Geburtshilfe
Universitätsklinikum Schleswig-Holstein / Campus Lübeck
Ratzeburger Allee 160
23538 Lübeck, Germany
Cornelia.Liedtke@uksh.de
Prof. Dr. med. Volkmar Müller
Klinik für Gynäkologie
Universitätsklinikum Hamburg-Eppendorf
Martinistrasse 52
20246 Hamburg, Germany
v.mueller@uke.de
Dr. med. Matthias Siebert
Universitäts-Frauenklinik
Operative Gynäkologie and Gynäkologische Onkologie
Universitätsspital Basel
Spitalstrasse 21
4031 Basel, Switzerland
matthias.siebert@usb.ch
PD Dr. med. Marc Thill
Klinik für Gynäkologie und Geburtshilfe
Agaplesion Markus Krankenhaus
Wilhelm-Epstein-Straße 4
60431 Frankfurt/M., Germany
marc.thill@fdk.info
tients with TNBC (‘+’), however, there are no data yet as to 
whether there are certain subgroups that show a higher 
response.
Müller: Carsten Denkert presented results from the 
GeparSixto trial evaluating mRNA markers associated with 
the immune system function. This study is important in the 
context of a growing interest in the immune system for 
tumor response to chemotherapy. The authors and other 
groups have observed a prognostic and predictive impact of 
tumor infiltrating lymphocytes. In their work presented at 
ASCO, they evaluate different states of immune activation 
by mRNA markers. In conclusion, they found that the exam-
ined immune suppressing markers are expressed together 
with pro-immune markers, suggesting a feedback activation 
of immunosuppressive pathways and immune reaction. 
Almost all of the examined markers had a predictive role for 
therapy response, underlining an important role of the im-
mune system.
Thill: Currently numerous different prognostic and pre-
dictive factors are under intense evaluation, but not really 
integrated in clinical trials. Therefore, one of the most im-
portant contributions regarding prognosis and prediction is 
the interim analysis of the ADAPT trial. Oleg Gluz et al. 
showed that the Ki67 value dropped down to <10% in 70% 
of the hormone-receptor positive, Her2/neu-negative breast 
cancer patients with an Oncotype DX® recurrence score be-
tween 12 and 25. Potentially, this is the group of patients in 
which chemotherapy can be avoided in future. The most 
promising contribution was presented by Carsten Denkert 
who described a correlation between immune subtypes and 
the response to chemotherapy in terms of a link between im-
mune markers and pCR. However, validation studies are 
needed.
Siebert: There were at least 2 important contributions 
about prognostic or predictive factors in my opinion: The 
PAM50 intrinsic subtyping showed a significant prognostic ef-
fect on relapse-free survival breast cancer patients treated 
with chemotherapy. Additionally, the predictive effect of 
tumor infiltrating lymphocytes (TILs) and lymphocyte pre-
dominant breast cancer was shown by an increased pCR rate 
in carboplatin treated TNBC (74%) and Her2/neu-positive 
(78%) breast cancer by Carsten Denkert as a result of the 
GeparSixto trial.
